Summary by Futu AI
Chisso Pharmaceuticals -B (2616) announced its interim performance for the six months ended June 30, 2024, as of June 30, 2024. The unaudited condensed consolidated results show that the company's revenue was RMB 254.2 million, a decrease of 2.8% compared to the same period last year. Among them, pharmaceutical sales revenue decreased by RMB 128.6 million, but licensing fee revenue increased by RMB 122.6 million. Research and development expenses decreased significantly by RMB 120.6 million to RMB 66.2 million, mainly due to a reduction in milestone costs, third-party contract costs, and employee costs. Administrative expenses also decreased by RMB 42.5 million to RMB 46.7 million. The company turned from a loss to a profit during the period, recording a surplus of RMB 15.7 million. Synximab received approval in the European Union for first-line treatment of adult patients with transferrable non-small cell lung cancer and reached a strategic commercialization partnership with Ewopharma AG. The company will hold an interim performance conference call on August 26, 2024. The board of directors does not recommend distributing interim dividends.
